hrp0094p1-53 | Bone B | ESPE2021

Growth and Puberty in Patients with Osteogenesis Imperfecta

Pınar Ozturk Ayşe , Ozturan Esin Karakılıc , Poyrazoğlu Şukran , Baş Firdevs , Darendeliler Feyza ,

Aim: Osteogenesis imperfecta (OI) is a genetic disease of extracellular matrix presenting with varying degrees of skeletal fragility. The study aims to evaluate growth and pubertal characteristics of 83 patients with OI.Materials and methods: Patients were classified according to Sillence clinical classification criteria. Demographic data, clinical findings, growth and pubertal characteristics were recorded from medical charts, retrospec...

hrp0094p1-128 | Growth A | ESPE2021

Evaluation of Persistent Short Stature in Children Born Small for Gestational Age without Catch-up Growth

Pınar Ozturk Ayşe , Ozturan Esin Karakılıc , Poyrazoğlu Şukran , Baş Firdevs , Darendeliler Feyza ,

Aim: The majority of children born small for gestational age (SGA) demonstrate spontaneous catch-up growth in height by the age of two years; however, approximately 10-15% of SGA newborns are at risk of having subnormal growth and persistent short stature (PSS).Method: We evaluated clinical, anthropometric, and laboratory characteristics of the 86 children with PSS who were born SGA.Results...

hrp0094p2-29 | Adrenals and HPA Axis | ESPE2021

Fludrocortisone is the salvage treatment in cases with calcineurin inhibitor related hyperkalemia

Unsal Yagmur , Baltu Demet , Gulhan Bora , Visal Okur Fatma , Duzova Ali , Ozon Alev , Topaloğlu Rezan , Gonc Nazlı ,

Calcineurin inhibitors (CNIs) are widely used in pediatric transplantation for prevention of graft rejection, prophylaxis and treatment of graft versus host disease. Though hyperkalemia is a common adverse effect (10-45%), alterations in renin-angiotensin-aldosterone system in CNI-induced hyperkalemia are not well elucidated. Consequently, CNIs vital to transplantation are usually switched. Here, we describe two cases with CNI-induced hyperkalemia due to hyporeninemic hypoaldo...

hrp0097p1-413 | Bone, Growth Plate and Mineral Metabolism | ESPE2023

Obesity and Insulin Resistance in Patients with Achondroplasia

İnan Balcı Elif , Derya Kardelen Aslı , Baş Firdevs , Yıldız Melek , Poyrazoğlu Şükran , Darendeliler Feyza

Background: Achondroplasia (ACH) is the most common skeletal dysplasia with an incidence of 1/20,000. Acanthosis nigricans (AN) is commonly seen in conditions associated with reduced insulin sensitivity. AN has been reported in association with skeletal dysplasias due to activating mutations in FGFR3, including ACH.Objective: Our aim was to evaluate insulin sensitivity and glucose metabolism in patients with ACH carrying...

hrp0097p1-419 | Bone, Growth Plate and Mineral Metabolism | ESPE2023

Evaluation of the pediatric patients diagnosed with secondary osteoporosis

Singin Berna , Donbaloğlu Zeynep , Barsal Çetiner Ebru , Aydın Behram Bilge , Ünver Tuhan Hale , Parlak Mesut

Objective: Secondary osteoporosis has a high rate of accompanying chronic diseases. We aimed to review the clinical and laboratory features, underlying causes, Dual Energy X-ray Absorptiometry (DEXA) results before and after treatment of patients diagnosed with secondary osteoporosis and to determine the relationship between this condition and fracture rates.Methods: This study was designed as a single-center, descriptiv...

hrp0097p1-358 | Pituitary, Neuroendocrinology and Puberty | ESPE2023

Do gonadotropin releasing hormone analogues increase the total body fat mass and body mass index in girls with idiopathic central precocious puberty?

Donbaloğlu Zeynep , Singin Berna , Barsal Cetiner Ebru , Aydin Behram Bilge , Bedel Aynur , Tuhan Hale , Parlak Mesut

Aim: Gonadotropin-releasing hormone analogues (GnRHa) are widely used in the treatment of idiopathic central precocious puberty (ICPP) cases due to premature maturation of the hypothalamus-pituitary-gonad axis. The effect of GnRHa therapy on body weight and fat distribution is controversial in the literature. We aimed to examine the anthropometric measurements and body composition analysis of the girls with ICPP and to investigate the effect of related factors...

hrp0095p1-541 | Multisystem Endocrine Disorders | ESPE2022

Severe Systemic Pseudohypoaldosteronism Type 1: 10 years of evolution

Luísa Carvalho Ana , Miguel Gomes Maria , Martins Sofia , Marques Olinda , Antunes Ana

Background: Type 1 pseudohypoaldosteronism (PHA1) is a rare syndrome characterized by unresponsiveness to aldosterone. Diagnosis is established by high levels of aldosterone and plasma renin activity, associated with findings of hypoaldosteronism (hyponatremia, hyperkalemia and metabolic acidosis). When the inheritance pattern is autosomal recessive it expresses as a severe systemic disease and the mortality rate is high, especially in the neonatal period....

hrp0095p2-177 | Growth and Syndromes | ESPE2022

Effects of Somatropin treatment in different groups of patients with indication for replacement therapy: isolated growth hormone deficiency, small for gestational age, Turner syndrome and Prader-Willi syndrome

Afonso Nuno , Luísa Carvalho Ana , Martins Sofia , Antunes Ana , Miguel Gomes Maria

Introduction: Somatropin has been the standard treatment for Growth hormone deficiency (GHD) since 1985. Nowadays, has been approved for the treatment of other diseases, as: Small for gestational age (SGA), Turner syndrome (TS) and Prader-Willi syndrome (PWS).Aims: Assess the efficacy of somatropin in children followed in a tertiary Hospital, at 12 and 24 months of treatment, and to compare the results based on the patie...

hrp0092p1-192 | Fat, Metabolism and Obesity (1) | ESPE2019

Changes in Objectively Measured Sleep Quality After an Integral Intervention in Patients with Abdominal Obesity

Azcona Cristina , Catalán Ana , Morell Lydia , Ojeda Ana , Chueca María , Marti Amelia

Aim: to study sleep quality, using accelerometry in children and adolescents with abdominal obesity after a multidisciplinary intervention.Patients, Material and Methods: we included 122 children and adolescents, range age: 7 to 16 years old, diagnosed with abdominal obesity (waist circumference > p90) who participated in an 8-week intervention program to lose weight, with a 2-year follow-up period. Participants were...

hrp0086p2-p512 | Fat Metabolism and Obesity P2 | ESPE2016

Weight Status in Children at 8 Years: A Prospective Cohort Study

Riano-Galan Isolina , Cristina Rodriguez-Dehli Ana , Olaya-Vazquez Ines , Fernandez-Somoano Ana , Tardon Adonina

Background: Prevalence of childhood obesity represents a major public health concern, given the tracking of body weight from childhood to adult age and its health sequelae.Objective: To describe prevalence of overweight (OW) and obesity (OB) in children at 8 years and investigate the relationship with pre-pregnancy maternal weight and weight status at 4 years.Methods: 485 pregnant mothers recruited between 2004 and 2007 and 409 chi...